早期类风湿关节炎完全撤药后复发再治疗:AVERT研究2年结果
AVERT研究2年结果显示,早期RA患者完全撤药后多数在6个月内复发,1年时仅少数维持缓解;复发后开放标签阿巴西普联合甲氨蝶呤再治疗6个月有效且耐受良好。
要点
- 早期RA完全撤药后多数在6个月内复发,1年持续缓解者少。
- 复发后再治疗6个月,76.6%达DAS28-CRP<3.2,62.9%达<2.6。
- 再治疗耐受良好,感染率低于初始治疗期。
核心结论
- 早期RA患者完全撤药后多数在6个月内复发,仅少数维持1年缓解。
- 复发后阿巴西普联合甲氨蝶呤再治疗有效且耐受良好。
研究设计与样本
- AVERT研究(NCT01142726)2年结果报告,患者最初随机双盲接受每周皮下阿巴西普联合甲氨蝶呤、阿巴西普单药或甲氨蝶呤单药治疗。
- 第12个月DAS28-CRP<3.2者快速撤停所有RA治疗,观察≤12个月或至复发。
- 撤药≥3个月后方案定义复发者接受开放标签阿巴西普联合甲氨蝶呤再治疗6个月。
主要发现
- 撤药第253天前,原阿巴西普联合甲氨蝶呤组和原阿巴西普组DAS28-CRP缓解比例数值上高于原甲氨蝶呤组。
- 撤药期末各组维持缓解者少:阿巴西普联合甲氨蝶呤组9/73(12.3%)、阿巴西普组7/50(14.0%)、甲氨蝶呤组6/53(11.3%)。
- 再治疗6个月后,95/124(76.6%)达DAS28-CRP<3.2,78/124(62.9%)达<2.6。
- 再治疗基线的DAS28-CRP和HAQ-DI平均变化分别为-2.87和0.76。
- 每100患者年暴露调整感染率:撤药期阿巴西普联合甲氨蝶呤组7.2,再治疗期17.2,初始治疗0-6月116.6、6-12月64.6。
关键数值与推荐
- 撤药条件为第12个月DAS28-CRP<3.2。
- 复发后再治疗方案为开放标签阿巴西普联合甲氨蝶呤治疗6个月。
- 再治疗疗效评价采用DAS28-CRP<3.2和<2.6阈值。
临床怎么用
- 早期RA达到DAS28-CRP<3.2后完全撤药需警惕6个月内复发风险。
- 复发后阿巴西普联合甲氨蝶呤再治疗可作为有效且耐受良好的选择。
局限性
- 再治疗为开放标签,非双盲对照。
- 撤药期末维持缓解者样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To complete reporting of outcomes after total withdrawal of all rheumatoid arthritis (RA) therapy and re-treatment after flare in Assessing Very Early Rheumatoid arthritis Treatment study (NCT01142726). METHODS: Patients with early RA were initially randomised to double-blind, weekly subcutaneous abatacept plus methotrexate, or abatacept or methotrexate monotherapy. At month 12, patients with Disease Activity Score (DAS)28 C reactive protein (CRP) <3.2 had all RA treatments rapidly withdrawn and were observed for ≤12 months or until flare. After ≥3 months' withdrawal, patients with protocol-defined RA flare received open-label abatacept plus methotrexate for 6 months (re-treatment). RESULTS: Proportion of patients in DAS28-CRP-defined remission remained numerically higher in original abatacept plus methotrexate and abatacept arms versus methotrexate arm up to day 253 of withdrawal. At the end of the withdrawal period, few patients remained in remission across all arms: 9/73 (12.3%), 7/50 (14.0%) and 6/53 (11.3%), respectively. For patients entering re-treatment, after 6 months' re-treatment, 95/124 (76.6%) and 78/124 (62.9%) patients achieved DAS28-CRP <3.2 and <2.6, respectively; mean changes in DAS28-CRP and Health Assessment Questionnaire-Disability Index scores from re-treatment baseline were -2.87 and 0.76, respectively. Re-treatment was well tolerated; exposure-adjusted infection rates per 100 patient-years were lower with abatacept plus methotrexate during withdrawal (7.2) and re-treatment (17.2) versus initial treatment periods of months 0-6 (116.6) and 6-12 (64.6). CONCLUSIONS: Most patients flared within 6 months of therapy withdrawal and few sustained major responses for 1 year. Re-treatment with abatacept plus methotrexate was effective and well tolerated in this controlled setting.
引用
- Emery P, Burmester GR, Bykerk VP, et al. Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open. 2019. PMID: 30997151. doi:10.1136/rmdopen-2018-000840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。